Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

Inclusion Criteria:

* Age 18 years or older.
* Female patient with stage II and III triple-negative breast cancer, requiring neoadjuvant chemo-immunotherapy according to the KEYNOTE-522 regimen or any neoadjuvant treatment including chemotherapy and immunotherapy validated in standard care or a clinical trial, regardless of the treatment regimen (ER \< 10%, PR \< 10%, HER2 0, and HER2 low).
* Patient requiring the placement of a localization clip as part of their standard clinical care management.
* Patient who has read the information sheet and signed the informed consent.
* Patient affiliated with a Social Security health insurance scheme.

Exclusion Criteria:

* Metastatic breast cancer documented by staging workup (PET scan or thoraco-abdomino-pelvic CT scan + bone scan).
* Patient who has undergone primary surgery.
* INR \< 1.5; Platelets \< 50,000/$\\mu$L.
* Patient presenting with multiple primary malignant tumors.
* Patient with HIV infection, Hepatitis C, or active Hepatitis B.
* Patient taking:
* Dual antiplatelet therapy: Acetylsalicylic acid + Clopidogrel without the possibility of suspending Clopidogrel for 5 days,
* Ticagrelor without the possibility of suspension for 5 days,
* Prasugrel without the possibility of suspension for 7 days,
* Vitamin K antagonists (acenocoumarol, warfarin, or fluindione) with INR \< 2 or \> 3, without the possibility of suspension.